- Home
- PRTA vs FDUS Comparison
PRTA vs FDUS Comparison
Compare PRTA & FDUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- FDUS
- Stock Information
- Founded
- PRTA 2012
- FDUS 2011
- Country
- PRTA Ireland
- FDUS United States
- Employees
- PRTA N/A
- FDUS N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- FDUS Finance/Investors Services
- Sector
- PRTA Health Care
- FDUS Finance
- Exchange
- PRTA Nasdaq
- FDUS Nasdaq
- Market Cap
- PRTA 809.8M
- FDUS 654.0M
- IPO Year
- PRTA N/A
- FDUS 2011
- Fundamental
- Price
- PRTA $6.58
- FDUS $20.76
- Analyst Decision
- PRTA Buy
- FDUS Hold
- Analyst Count
- PRTA 9
- FDUS 1
- Target Price
- PRTA $27.67
- FDUS $20.00
- AVG Volume (30 Days)
- PRTA 1.7M
- FDUS 208.1K
- Earning Date
- PRTA 08-07-2025
- FDUS 07-31-2025
- Dividend Yield
- PRTA N/A
- FDUS 10.86%
- EPS Growth
- PRTA N/A
- FDUS N/A
- EPS
- PRTA N/A
- FDUS 2.33
- Revenue
- PRTA $137,935,000.00
- FDUS $147,999,000.00
- Revenue This Year
- PRTA N/A
- FDUS $4.94
- Revenue Next Year
- PRTA $119.20
- FDUS $6.51
- P/E Ratio
- PRTA N/A
- FDUS $8.93
- Revenue Growth
- PRTA 54.55
- FDUS 9.06
- 52 Week Low
- PRTA $4.32
- FDUS $16.70
- 52 Week High
- PRTA $25.42
- FDUS $23.55
- Technical
- Relative Strength Index (RSI)
- PRTA 59.96
- FDUS 62.73
- Support Level
- PRTA $5.96
- FDUS $19.77
- Resistance Level
- PRTA $6.59
- FDUS $21.07
- Average True Range (ATR)
- PRTA 0.38
- FDUS 0.28
- MACD
- PRTA 0.15
- FDUS 0.09
- Stochastic Oscillator
- PRTA 83.93
- FDUS 79.87
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About FDUS Fidus Investment Corporation
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investments is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.